Tilray Has Little Upside Left in 2021 After 33% Surge, Analyst Says
While Sen. Chuck Schumer (D-N.Y.) is preparing federal legislation on marijuana legalization, CIBC analyst John Zamparo says it's not going to benefit Tilray (NASDAQ: TLRY) this year, even if it is a positive catalyst for the company over the long term.
So in the wake of Tilray's 33% share price run-up following its acquisition of Aphria, Zamparo downgraded the marijuana producer's stock because, in his view, there's little upside left right now.
Image source: Getty Images.
Source Fool.com
